EE200400085A - 2-amino-6-(2,4,5-asendatud fenüül)püridiinid kasutamiseks lämmastikoksiidi süntaasi inhibiitoritena - Google Patents

2-amino-6-(2,4,5-asendatud fenüül)püridiinid kasutamiseks lämmastikoksiidi süntaasi inhibiitoritena

Info

Publication number
EE200400085A
EE200400085A EEP200400085A EEP200400085A EE200400085A EE 200400085 A EE200400085 A EE 200400085A EE P200400085 A EEP200400085 A EE P200400085A EE P200400085 A EEP200400085 A EE P200400085A EE 200400085 A EE200400085 A EE 200400085A
Authority
EE
Estonia
Prior art keywords
pyridines
amino
substituted phenyl
nitric oxide
oxide synthase
Prior art date
Application number
EEP200400085A
Other languages
English (en)
Estonian (et)
Inventor
Adams Lowe John Iii
Alfred Volkmann Robert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200400085A publication Critical patent/EE200400085A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
EEP200400085A 2001-10-10 2002-09-24 2-amino-6-(2,4,5-asendatud fenüül)püridiinid kasutamiseks lämmastikoksiidi süntaasi inhibiitoritena EE200400085A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32825301P 2001-10-10 2001-10-10
PCT/IB2002/003939 WO2003030993A1 (en) 2001-10-10 2002-09-24 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors

Publications (1)

Publication Number Publication Date
EE200400085A true EE200400085A (et) 2004-08-16

Family

ID=23280189

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400085A EE200400085A (et) 2001-10-10 2002-09-24 2-amino-6-(2,4,5-asendatud fenüül)püridiinid kasutamiseks lämmastikoksiidi süntaasi inhibiitoritena

Country Status (37)

Country Link
EP (1) EP1434624B1 (pl)
JP (1) JP2005506337A (pl)
KR (1) KR20040053157A (pl)
CN (1) CN1568207A (pl)
AP (1) AP2004003003A0 (pl)
AR (1) AR036763A1 (pl)
AT (1) ATE344089T1 (pl)
BG (1) BG108669A (pl)
BR (1) BR0213193A (pl)
CA (1) CA2463364A1 (pl)
CZ (1) CZ2004450A3 (pl)
DE (1) DE60215837T2 (pl)
DO (1) DOP2002000467A (pl)
EA (1) EA007074B1 (pl)
EC (1) ECSP045055A (pl)
EE (1) EE200400085A (pl)
ES (1) ES2275917T3 (pl)
GT (1) GT200200206A (pl)
HN (1) HN2002000289A (pl)
HR (1) HRP20040260A2 (pl)
HU (1) HUP0401678A3 (pl)
IL (1) IL161089A0 (pl)
IS (1) IS7171A (pl)
MA (1) MA27074A1 (pl)
MX (1) MXPA04002313A (pl)
NO (1) NO20041411L (pl)
NZ (1) NZ531591A (pl)
OA (1) OA12664A (pl)
PA (1) PA8556101A1 (pl)
PE (1) PE20030478A1 (pl)
PL (1) PL369454A1 (pl)
PY (1) PY0223361A (pl)
SK (1) SK1642004A3 (pl)
TN (1) TNSN04057A1 (pl)
UY (1) UY27476A1 (pl)
WO (1) WO2003030993A1 (pl)
ZA (1) ZA200401747B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
US20080070952A1 (en) * 2005-02-21 2008-03-20 Proximagen Ltd., Inhibition or Treatment of Dyskinesia
US9540361B2 (en) * 2010-12-24 2017-01-10 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
RU2637503C1 (ru) * 2016-12-30 2017-12-05 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) Способ получения n2-метилдезоксигуанозина

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA49006C2 (uk) * 1996-03-29 2002-09-16 Файзер Інк. Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування
WO1998034919A1 (en) * 1997-02-10 1998-08-13 Pfizer Products Inc. 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
PL358538A1 (pl) * 1999-05-21 2004-08-09 Pfizer Products Inc. Nowe środki farmaceutyczne dla inbibitorów NOS

Also Published As

Publication number Publication date
PY0223361A (es) 2004-04-01
OA12664A (en) 2006-06-19
SK1642004A3 (sk) 2005-04-01
NO20041411L (no) 2004-04-02
DE60215837D1 (de) 2006-12-14
KR20040053157A (ko) 2004-06-23
PL369454A1 (pl) 2005-04-18
MA27074A1 (fr) 2004-12-20
HUP0401678A3 (en) 2007-05-02
HUP0401678A2 (hu) 2004-12-28
PE20030478A1 (es) 2003-06-06
ECSP045055A (es) 2004-05-28
EA200400321A1 (ru) 2004-08-26
UY27476A1 (es) 2003-05-30
DOP2002000467A (es) 2003-04-15
AR036763A1 (es) 2004-09-29
CA2463364A1 (en) 2003-04-17
BG108669A (bg) 2005-03-31
HRP20040260A2 (en) 2004-12-31
BR0213193A (pt) 2004-08-31
MXPA04002313A (es) 2005-04-08
ES2275917T3 (es) 2007-06-16
CN1568207A (zh) 2005-01-19
DE60215837T2 (de) 2007-05-16
EP1434624A1 (en) 2004-07-07
CZ2004450A3 (cs) 2005-03-16
PA8556101A1 (es) 2003-07-28
EP1434624B1 (en) 2006-11-02
JP2005506337A (ja) 2005-03-03
AP2004003003A0 (en) 2004-03-31
IS7171A (is) 2004-03-04
NZ531591A (en) 2006-04-28
ZA200401747B (en) 2005-03-03
HN2002000289A (es) 2002-12-03
GT200200206A (es) 2003-05-23
EA007074B1 (ru) 2006-06-30
WO2003030993A1 (en) 2003-04-17
IL161089A0 (en) 2004-08-31
TNSN04057A1 (fr) 2006-06-01
ATE344089T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
NO20033288L (no) Anilinderivater som kan anvendes som fosfodiesterase 4- inhibitorer
DK1265860T3 (da) Amidinoforbindelse og salte deraf, der er nyttige som nitrogenoxidsyntaseinhibitorer
DK1581532T3 (da) Pyrazolo-3,4-B pyridinforbindelser og deres anvendelse som phosphodiesterase inhibitorer
NO20041293L (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
ATE445615T1 (de) Pyrido(2,1-a)isochinolinderivative als dpp-iv- hemmer
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20042097L (no) Naftyridinderivater, deres fremstilling og deres anvendelse som fosfodiesterase-isoenzym 4-(PDE4) inhibitorer.
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
NO20034042D0 (no) Metallproteinase-inhibitorer
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
DK1317421T3 (da) 2-amino-2-alkyl-5-heptensyre- og heptynsyrederivater der er nyttige som nitrogenoxidsynthaseinhibitorer
DE02796975T1 (de) Hochtemperatur-gasreformier-zykloverbrennungsvorrichtung
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
NO20055518D0 (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
PL369454A1 (pl) 2-amino-6-(2,4,5-podstawione-fenylo)-pirydyny do stosowania jako inhibitory syntazy tlenku azotu
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
DZ3441A1 (fr) Nouvelles phenylpiperazines.
NO20054289D0 (no) Imiciazo[4,5-b]kinolinderivater og dem anvendelse som NO-syntaseinhibitorer
ATE297382T1 (de) 3-heterocyclyl propanohydroxamsäure-derivaten als pcp inhibitoren
ITTO20020015A0 (it) Attrezzo di molatura per applicazioni odontotecniche.
NO20022475D0 (no) Ovn
ES1049329Y (es) Ladrillo perfeccionado.